Background: The prognostic implications of p53 accumulation, bcl-2 immunoreactivity and tumour proliferative fraction in ovarian carcinomas are still debated.
Introduction
The prognosis of advanced-stage ovarian cancer patients has remained largely unchanged over the past decade following the introduction of platinum-based therapeutic regimens [1] . The available clinico-pathological prognostic factors have thus far proven insufficient to clearly define prognostic subgroups and identify the patients who could benefit from additional treatments or more intensive therapeutic regimens.
Several studies have been devoted to identifying novel prognostic indicators for ovarian carcinomas, but the actual prognostic and/or predictive implications of a variety of biological parameters (c-erbB-2 gene amplification and product overexpression, p53 gene aberration and protein accumulation, bcl-2 expression, tumour growth fraction and ploidy) in these malignancies are still highly controversial. Indeed, it is exceedingly difficult to ascertain from the currently available data whether and/or the extent to which evaluation of the above parameters contributes to a better definition of the biology and clinical behaviour of ovarian carcinomas, in addition to the information already provided by the conventional clinical (age, performance status, type of adjuvant chemotherapy) and pathological (histological type, grade and stage of the neoplasms, presence of ascites, rupture of the tumours during primary surgery, amount of residual disease after surgical treatment) prognostic indicators.
The aim of this investigation was to assess the prognostic and predictive implications of p53 accumulation, bcl-2 expression and tumour proliferative fraction (as evaluated by the MIB1 monoclonal antibody against the Ki-67 antigen) [2] in a series of 112 ovarian carcinoma patients. The results have been correlated with patient survival after adjustment for age and performance status, histological type, grade and stage of the neoplasms and for the persistence of residual disease after primary surgery.
The possible prognostic value of/755 aberrations in ovarian carcinomas has been addressed in several studies, many of which documented an adverse prognostic effect otp53 protein accumulation in univariate analysis [3] [4] [5] [6] [7] . In particular, we previously showed in a series of 98 ovarian carcinoma patients -who are now incorporated into this larger series -that nuclear accumulation of p53 protein in more than 10% of neoplastic cells was significantly correlated with worse disease-free and overall survivals [3] . The prognostic value of p53 protein accumulation or p53 gene aberration, however, was refuted in other studies [8, 9] and lost when multivariate analyses of the results were performed [4, 6, 10] . Herod et al. [10] reported a weak prognostic importance otp53 accumulation in ovarian carcinomas when it occurred in more than 75% of neoplastic cells and the histological type was excluded from the multivariate model.
Bcl-2 expression in ovarian carcinoma has been far less extensively investigated. A correlation of bcl-2 expression with better survival in ovarian carcinoma patients, and an inverse correlation with the accumulation ofp53 have recently been documented [10, 11] . Bcl-2 immunoreactivity in 18 of 30 ovarian carcinomas has also been reported by Eliopoulos et al. [12] , but in their experience there was a positive correlation between bcl-2 andp53 immunostaining.
The tumour proliferative fraction of ovarian carcinomas has been investigated immunohistochemically by means of antibodies recognising cell cycle-related antigens (Ki-67 and PCNA) and/or by evaluation of the S-phase fraction by flow cytometry. An adverse effect of high proliferation indexes on overall [1, [13] [14] [15] [16] or disease-free [13, 17] survival has been consistently reported; an exception has been the findings of Hartmann et al. [18] , who documented a better survival for patients with tumours having a proliferative index (PCNA immunostaining) higher than the median value. Multivariate analysis of the results, however, was performed in only one study [17] , which documented a significant relationship between Ki-67 immunostaining and disease-free survival, independent of histologic grade and disease stage.
Patients and methods

Patients
The study population consisted of 112 consecutive ovarian carcinoma patients surgically treated at the St. Bortolo Hospital in Vicenza (67 patients) and at the St. Paolo Hospital of the University of Milan (45 patients). The mean follow-up was 46 months (range 3-148 months). The main clinical and pathological characteristics of the patients are listed in Table 1 .
Criteria for inclusion in the study were histologically-proven diagnosis of invasive common epithelial cancer (borderline or low malignant potential neoplasms were excluded), no treatment of the disease prior to surgery, sufficient archival tumour tissue for immunocytochemical investigations, follow-up information, and no other previous or concomitant primary invasive carcinoma (except for basal cell carcinoma of the skin).
Pathological examination
Tumours were pathologically staged according to the International Federation of Gynaecology and Obstetrics (FIGO) standards [19, 20] . Two of the authors (GV, EB) reviewed the original histological slides and classified the tumours in relation to their predominant histologic type [21] . A mean of 6.1 sections of the primary tumour were reviewed per case (range, 2 to 15). A single tumour without a recognisable predominant histologic pattern (i.e., over 50% of the whole tumour) was classified as mixed carcinoma. Histologic grading was defined by the architectural and cytological grade and was performed using conventional criteria [21] .
Treatment
Patients with FIGO stages I and II disease underwent standard operative procedures (abdominal hysterectomy, bilateral salpingooophorectomy, and omentectomy with careful examination of all serosal surfaces, biopsies of any suspected lesion and sampling of retroperitoneal lymph nodes), and peritoneal washings for cytological studies Patients with FIGO stage III and IV disease were subjected to standard operative procedures; in all cases an attempt was made to optimally debulk the grossly recognisable tumour, and the amount of residual disease at completion of debulking surgery was recorded as none, less than or equal to 2 cm, and more than 2 cm. Postoperatively, all patients were treated with induction platinum-based combination chemotherapy regimens (cisplatin, doxorubicin or epirubicin, and cyclophosphamide in 19 cases, cisplatin and cyclophosphamide in 25 cases, and carboplatin and cyclophosphamide in 15 cases). The median number of cycles of induction chemotherapy administered was 6 (range 2 to 9). Approximately one month after the last course of induction chemotherapy clinical response to treatment was assessed. A complete clinical response (CR) was defined as the disappearance of all parameters of disease for more than two months; partial response (PR) was defined as a > 50% reduction in the size of all lesions for at least two months, progressive disease was defined as a > 25% growth of any lesion or as any development of new lesions. Stable disease was defined as any response with a < 50% reduction in the size of all lesions or as a tumour growth < 25%. Clinically complete responders underwent second-look laparoscopy. In laparoscopy-negative patients, second-look laparotomy was performed to assess the pathologic response, using conventional surgical and pathologic procedures. The patients who achieved a pathologic CR or a PR were considered responsive to therapy. The sites of persistence and the volume of residual disease after induction chemotherapy were carefully histologically assessed.
Patients who initially had only an exploratory laparotomy underwent a second laparotomy after chemotherapy for cytoreduction. Further management depended on the results of these procedures. In general, patients responding to chemotherapy received three to four additional cycles of the same combination chemotherapy Those with non-responsive disease were treated with a salvage second-line chemotherapy.
Every three months a complete physical and gynaecological examination of the patients was performed. A CT scan was done every six months during the first two years or more often if clinically indicated.
Immunotytochemistry
Consecutive formalin-fixed, paraffin embedded tissue sections of the most representative tissue block of the tumours with minimal necrosis and inflammation were immunostained for the p53 (PAbl801 monoclonal antibody [Mab] , Oncogene Science, Cambridge, MA, used at 1:2,000 dilution), bd-2 (124 Mab, Dako, Glostrup, Denmark, at 1:200 dilution) and K.i-67 (MIB1 Mab, Immunotech, Marseille, France) using a conventional avidin-biotinylated peroxidase complex (ABC) staining method [22] , as previously reported [23] . An antigen retrieval pre-treatment of the tissue sections with citrate buffer (pH6) in a microwave oven was performed for all immunoreactions [24] .
Formalin-fixed paraffin-embedded sections of a follicular nonHodgkin's lymphoma carrying the t(14;18) chromosomal translocation were immunostained as a positive control for bcl-2 immunoreactivity, while a colon carcinoma with abnormal nuclear accumulation of p53 protein and a point mutation in exon 5 of ihe p53 gene [25] was used as positive control (or p53 immunostaining. These control sections displayed strong immunoreactivity for the corresponding antigens in all staining runs
Negative control sections were incubated with the immunoglobulin fraction of normal mouse serum, and the results were consistently unstained.
The immunoreactivity for bcl-2 and p53 was semiquantitatively evaluated with respect to the percentage of immunostained tumour cells (-: no immunostained cells; +: less than 10%; ++. 10%-50%, and +++: more than 50% immunoreactive cells); for MIB1 labelling, the actual percentage of stained cells over at least 2,000 tumour cells was recorded.
Statistics
All analyses were carried out using SAS statistical software (SAS Institute, Inc, Cary, NQ. Pearson's correlation coefficients were used for examining the association between different measures [26] . For overall survival (OS), the endpoint of the analysis was death from any cause [27] ; subjects still alive at the end of the study or known to be alive at some time and then lost to follow-up were right censored. Plots of the estimated survival function against time were drawn. For comparison of survival curves, two rank tests (Wilcoxon and logrank) were adopted [28] . The Cox proportional hazard regression model [29] was used to evaluate the effect of explanatory variables on survival time. Factors were added stepwise to the model. The most statistically significant factor was selected first (with Pr Chi-square < 0.25), and a search was then made for the next factor that, together with the first factor, best predicted survival. This process was continued, with factors added until there was no longer an improvement in prediction, as judged by an increase in the log-likelihood value. All factors entered into the model which did not meet the criteria (Pr Chisquare <0.l5) for remaining in were removed in a step-down phase. All P-values were based on two-sided testing.
Results
p53 accumulation
Nuclear p53 accumulation was documented in 70 (62.5%) of the 112 cases. Sixty-one (54.5%) of the cases showed accumulation in more than 10% of neoplastic cells and were considered positive for subsequent correlations. Cytoplasmic immunoreactivity was never encountered.
p53 accumulation was positively correlated with grade (r = 0.313; P = 0.001) and stage (r = 0.294; P -0.002) of the neoplasms, and with the persistence of more than a 2-cm residual tumour after primary surgery (r = 0.200; P -0.039), whereas it was unrelated to the tumour histotype or the other clinical variables under study.
bcl-2 immunoreactivity
Bcl-2 immunoreactivity was observed in 52 (46.4%) cases: it was restricted to the cell cytoplasm, and was of the same staining intensity as that of the tumour-infiltrating lymphocytes. Forty-two (37.5%) cases exhibited protein expression in more than 10% of neoplastic cells, and were considered positive for subsequent statistical analyses.
Bcl-2 immunoreactivity was not correlated with type, stage or grade of the tumours, or with any other clinical variable examined.
Proliferative fraction
MIB1 labelling index (L.I.) ranged from 1% to 90% of the neoplastic cells, with a median value of 30% This was taken as the cut-off to distinguish low from highly proliferative cases, when the values were analysed in a dichotomised manner.
The MIB1 L.I. was positively correlated with grade (r = 0.260; P -0.007) and stage (r = 0.234; P = 0.014) of the neoplasms when analysed as both a continuous and a dichotomised variable. There was no correlation with tumour type or the other clinical variables examined.
Correlations among p53, bcl-2 and MIB1 immunoreactivities
There was a positive correlation between p53 accumulation and MIB1 L.I. (r = 0.235; P -0.015), whereas no significant correlation was found between p53 and bcl-2, or*c/-2andMIBlL.I.
Analysis of survival
In the entire patient population, the OS was significantly correlated to age, grade, stage, serous type, p53 accumulation, MIB1 L.I. (both continuous and dichotomised), performance status, and amount of residual tumour after primary surgery (Table 2) . Furthermore, patients were stratified according to tumour immunoreactivity for p53 combined with the MIB1 L.I. A very strong adverse effect on patient survival was ascertained for the simultaneous occurrence of p53 accumulation and MIB1 L.I. higher than 30% (P < 0.001) (Figure 1) .
In multivariate analysis, only age, stage, and p53 accumulation combined with high MIB1 L.I. retained an independent prognostic value (Table 3) .
When the patients were stratified according to disease stage (I and II vs. Ill and IV), in stage III and IV patients (Table 4) , age, performance status, mucinous histotype, p53 accumulation, MIB1 L.I., and the persistence of residual tumour were significantly correlated with a worse survival. Again, p53 accumulation combined with high MIB1 L.I. showed a significant correlation with patient survival (P = 0.034, Figure 2) .
In multivariate analysis (Table 5) , only performance status, mucinous type, persistence of residual disease, and p53 accumulation combined with MIB1 L.I. higher than 30% retained an independent prognostic value.
In stages I and II patients, age, grade, serous type and p53 accumulation were correlated with survival in univariate analysis, but they showed no independent prog- nostic significance in multivariate analysis. The simultaneous occurrence of p53 accumulation and MIB1 L.I. higher than 30%, however, had a very strong adverse effect on OS in both univariate (P < 0.001) and multivariate (P = 0.017) analyses (Table 6) .
Prediction of response to induction chemotherapy (FIGO stages III and IV)
A pathology-proven response to adjuvant chemotherapy (complete and partial remission vs. all others) was predicted by age (P -0.005) and performance status (P -0.032) only. When adjusted for age, however, performance status lost its significance. Bcl-2 immunoreactiv- ity, p53 accumulation, and MIBl L.I. (both alone and combined with p53 accumulation) showed no correlation with response to the therapy.
Discussion
This report describes an investigation of the prognostic implications of/>55 accumulation, bcl-2 immunoreactivity and MIBl L.I. in ovarian carcinomas. To our knowledge, it is the largest study to have dealt with prognostic indicators in ovarian carcinoma patients, and to have evaluated the independent prognostic value of various parameters using multivariate analysis of survival.
In the entire population, the OS was significantly correlated with a large number of variables including patient age and performance status, stage and grade of the tumours and amount of residual disease after primary surgery. These findings confirm the reliability of clinico-pathological parameters for the prognostic evaluation of ovarian cancer patients, as has frequently been reported in the pertinent literature [30] [31] [32] [33] . Furthermore, p53 nuclear accumulation in more than 10% of neoplastic cells and MIBl L.I. higher than 30% showed a statistically significant relation to reduced overall survival. When the latter two parameters were combined, they were strongly predictive of the highest risk ratio of death. In multivariate analysis, the simulta- neous occurrence of p53 accumulation and high MIBl L.I. was the most powerful prognostic indicator of reduced survival, followed by patient age, stage and grade of the tumours. None of the other parameters retained an independent prognostic value in multivariate analysis. Analysis of OS yielded similar findings when it was restricted to advanced-stage (FIGO stage III and IV) patients. In this subgroup of patients, independent prognostic parameters were tumour grade, mucinous type, persistence of residual disease, performance status, and high MIBl L.I combined with the simultaneous occurrence of p53 accumulation. Finally, in FIGO stages I and II patients, p53 accumulation combined with high MIBl L.I. was the only independent prognostic parameter of reduced OS. In accord with previous reports [3] [4] [5] [6] [7] , nuclear p53 accumulation was ascertained in more than 50% of ovarian carcinomas, and was correlated with a reduced OS.Though the PAbl801 Mab does not distinguish mutated from wildtype p53 proteins, it has frequently been reported that nuclear accumulation of p53 protein is significantly associated with missense mutations in exons 5 through 8 of the p53 gene, which lead to the synthesis of ineffective mutated proteins [9, 34] . The concordance betweeen p53 protein accumulation and p53 gene mutations, however, varies greatly: Greenblatt et al. [35] reviewed 84 studies in which both immunohistochemistry and gene sequence were performed on the same tumours. In these studies, the sensitivity of immunohistochemistry was 75% (range: 36%-100%) and the positive predicted value was only 63% (range: 8%-100%). Loss of function of the p53 tumour suppressor gene product (either as a result of gene abnormalities or of protein degradation and nuclear exclusion) would result in an uncontrolled cell growth and an impaired apoptotic pathway [36, 37] . This might be highly relevant for tumour formation and progression as well as for response to chemo-and radiotherapy. At least in some human tumours, it is likely that p53-dependent apoptosis can modulate the toxic effects of anticancer agents [38] .
Mutations of the p53 gene and/or abnormal accumulation of the protein have been recorded in most human malignancies, although the actual prognostic implications of these abnormalities are still highly controversial [39] . This is also true of ovarian carcinomas, in which the correlation between p53 accumulation and patient survival is lost after multivariate analysis in this as well as previous investigations [4, 6] . This is probably because p53 accumulation is strictly related to grade and stage of the tumours, to the amount of residual tumour after primary surgery, and to high tumour proliferative fraction [40] .
Although in our series of patients (considered as an entire population or stratified according to disease stage) neither p53 accumulation nor MIB1 L.I. alone provided independent prognostic information on OS, the simultaneous occurrence of p53 accumulation and high MIB1 L.I. turned out to represent a powerful and independent prognostic indicator. The combined evaluation of these two parameters (which can be easily accomplished in routinely fixed and embedded tissue sections) makes it possible to neatly separate subgroups of ovarian carcinoma patients with poor prognoses in both early-and advanced-stage disease.
We were unable to document any correlation between bcl-2 immunoreactivity (a feature of more than 10% of neoplastic cells in 37.5% of the cases) and OS in ovarian carcinoma patients, analogous to the findings of Jussila and Stenback [41] . Bcl-2 protein is effective in preventing apoptosis in a number of physiological and pathological conditions [42, 43] , and it has been implicated in the development of malignant lymphomas as well as of nonlymphoid malignancies [44] . In some human tumours, bcl-2 overexpression is correlated with a favourable clinical outcome independently of other prognostic parameters [45, 46] , whereas it has no independent effect on the survival of patients with other neoplasms [47] . A positive correlation between bcl-2 immunostaining and prolonged survival has recently been reported also for ovarian carcinomas [10, 11] . Herod et al. [10] documented a weak independent prognostic significance of bcl-2 expression in patients with tumours exhibiting more than 75% of immunoreactive neoplastic cells, and only when more powerful prognostic indicators, such as histological type of the tumours, were excluded from the multivariate model. In our series, bcl-2 immunoreactivity also failed to correlate with survival when the cut-off value between negative and positive cases was increased to more than 50% of immunoreactive neoplastic cells.
We also had the opportunity to evaluate the possible effects of all of the variables under study on the likelihood of response to chemotherapy in FIGO stages III and IV patients. While age and performance status showed a correlation with response, p53, bcl-2 and MIB1 immunoreactivities had no influence. This is at variance with experimental data on ovarian cell lines showing overexpression of bcl-2 and/or p53 in cells which had developed an in vitro resistance to cisplatin [12] , and with data on a small series of advanced-stage ovarian carcinoma patients in whom tumours overexpressing the wild-type p53 gene or carrying p53 gene mutations were found to be refractory to the therapy [48] . Our findings, however, are in agreement with the more recent observation in 70 patients of a lack of association between response to chemotherapy and p53 or bcl-2 immunoreactivity [10] . It is worth noting that the current series of cases has also been investigated for microvessel density, a measure of tumour angiogenesis, which turned out to be predictive of the response to chemotherapy, both in univariate and multivariate analyses [49] .
In conclusion, our results indicate that the combined evaluation ofp53 accumulation and MIB1 L.I. provides independent prognostic information on the OS of ovarian carcinoma patients with both early-and advanceddisease stages. This may be instrumental in defining subgroups of patients in whom it would be beneficial to administer additional treatment modalities or more intense therapeutic regimens.
